Working… Menu
Trial record 1 of 2 for:    ATRC
Previous Study | Return to List | Next Study

First-in-Human Dose Escalation Trial of ATRC-101 in Adults With Advanced Solid Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04244552
Recruitment Status : Recruiting
First Posted : January 28, 2020
Last Update Posted : February 1, 2021
Information provided by (Responsible Party):
Atreca, Inc.

Brief Summary:
ATRC-101-A01 is a first-in-human, Phase 1b, open-label trial to characterize the safety, tolerability, pharmacokinetics (PK), and biological activity of escalating doses of ATRC-101, an engineered, fully human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally-occurring human antibody.

Condition or disease Intervention/treatment Phase
Breast Cancer Colorectal Cancer Ovarian Cancer Non Small Cell Lung Cancer Acral Lentiginous Melanoma Biological: ATRC-101 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 65 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A First-in-Human Phase 1b Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 in Adults With Advanced Solid Malignancies
Actual Study Start Date : February 11, 2020
Estimated Primary Completion Date : December 2024
Estimated Study Completion Date : March 2025

Arm Intervention/treatment
Experimental: ATRC-101 Dose Escalation Biological: ATRC-101
ATRC-101 is an engineered, fully-human IgG1 antibody derived from a naturally-occurring human antibody.

Primary Outcome Measures :
  1. Incidence of DLTs, treatment emergent adverse events (TEAEs), and changes in safety parameters [ Time Frame: 24 months ]

Secondary Outcome Measures :
  1. Maximum plasma concentration (Cmax) of ATRC-101 [ Time Frame: 24 months ]
  2. Elimination half-life (t1/2) of ATRC-101 [ Time Frame: 24 months ]
  3. Area under the plasma concentration-time curve from zero to the last measurable concentration [AUC(0-t)] of ATRC-101 [ Time Frame: 24 months ]
  4. Incidence of anti-drug antibodies (ADAs) and ATRC-101 neutralizing antibodies [ Time Frame: 24 months ]
  5. Best Overall Response Rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 [ Time Frame: 24 months ]
  6. Enumeration of tumor-infiltrating CD8+ lymphocytes (TILs) in tumor biopsy specimens at baseline and during treatment [ Time Frame: 24 months ]
  7. Distribution of tumor-infiltrating CD8+ lymphocytes (TILs) in tumor biopsy specimens at baseline and during treatment [ Time Frame: 24 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Confirmed diagnosis of metastatic or unresectable breast cancer, NSCLC, colorectal cancer, ovarian cancer, or acral melanoma that is refractory to standard therapy or for which no standard therapy exists. Participants who are considered intolerant of or ineligible for standard therapy(ies), as well as participants who have been offered but refused standard therapy(ies), may also be eligible.
  • Measurable disease based on RECIST v1.1
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  • Adequate organ and marrow function (i.e. without chronic, ongoing growth factor or transfusion support) at Screening
  • Available representative tumor specimens in paraffin blocks (preferred) or ≥ 20 unstained slides, with an associated pathology report, obtained after last systemic anti-cancer therapy and within 60 days prior to the planned first dose of investigational product.
  • Women of childbearing potential (WOCBP) and fertile males with partners who are WOCBP must use highly effective contraception (per CTFG 2014) from first dose and through 90 days after final dose of investigational product
  • Willing and able to provide written informed consent and able to comply with all trial procedures.

Exclusion Criteria:

  • Malignant disease other than the malignancy to be investigated in this trial within the last 5 years with the exception of basal or squamous cell carcinoma of the skin OR curatively treated in situ disease.
  • Primary immunodeficiency affecting cellular immunity (2017 IUIS Classification)
  • Active autoimmune disease with the exception of Type I Diabetes Mellitus, hypothyroidism requiring hormone replacement only, an autoimmune dermatologic condition that is managed without systemic therapy, or autoimmune arthritis that is managed without systemic therapy
  • Active or prior paraneoplastic neurologic disorder of the central nervous system (CNS)
  • Prior allograft
  • Clinically significant cardiovascular disease, e.g., cerebral vascular accident/stroke or myocardial infarction, within 6 months prior to the first dose of investigational product, unstable angina, congestive heart failure (New York Heart Association ≥ Class III), or unstable cardiac arrhythmia requiring medication
  • Presence of active, symptomatic, or untreated CNS metastasis; or CNS metastasis that requires local directed therapy or increasing doses of corticosteroids within the 2 weeks prior to the planned first dose of investigational product. Individuals with treated and/or asymptomatic CNS disease may be enrolled if neurologically stable over the prior 2 weeks (after consultation with the Medical Monitor)
  • HIV infection with an AIDS-defining opportunistic infection within the past 12 months or with a CD4+ T cell count <350/µL
  • Hepatitis B surface antigen (HBsAg) positive OR anti-Hepatitis B core (anti-HBc) positive and HBV viral load above the lower limit of quantification
  • Hepatitis C antibody positive with HCV viral load greater than or equal to the lower limit of quantification
  • Infection requiring intravenous antibacterial, antiviral, or antifungal therapy within 2 weeks prior to the planned first dose of investigational product
  • Ongoing ≥ Grade 2 toxicity(ies) due to a previously administered anticancer agent with the following exceptions:

    • Grade 2 neuropathy or alopecia
    • Grade 2 immune-related endocrinopathy attributed to a checkpoint inhibitor and controlled with hormone replacement alone
  • Treatment with biological agents (including monoclonal antibodies) within 28 days of the planned first dose of investigational product
  • Treatment with radiation, chemotherapy or anticancer small molecule therapy within 14 days or 5 half-lives (whichever is longer) prior to the planned first dose of investigational product. Treatment with nitrosoureas or mitomycin C require a 42-day washout prior to the planned first dose of investigational product
  • Receipt of any investigational drug or device not otherwise specified above within 14 days or 5 half-lives (whichever is longer) prior to the planned first dose of investigational product
  • Pregnant or breastfeeding; negative pregnancy status in WOCBP must be confirmed by serum pregnancy test at Screening
  • Known allergy/intolerance to ATRC-101 or its excipients; or history of ≥ Grade 3 infusion reaction associated with antibody administration
  • Major surgery or significant traumatic injury occurring within 28 days prior to the planned first dose of investigational product. If major surgery occurred > 28 days prior to Cycle 1-Day 1, individual must have recovered adequately from the toxicity and/or complications from the intervention prior to Cycle 1-Day 1
  • Prior treatment with ATRC-101
  • Intercurrent illness that is either life-threatening or of clinical significance such that it might limit compliance with trial requirements, or in the Investigator's assessment would place the participant at an unacceptable risk for participation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04244552

Layout table for location contacts
Contact: Nick Higgins 650-453-5279

Layout table for location information
United States, Arizona
Mayo Clinic Recruiting
Phoenix, Arizona, United States, 85054
United States, California
City of Hope Recruiting
Duarte, California, United States, 91010
University of California, Los Angeles Hematology/Oncology Recruiting
Los Angeles, California, United States, 90095
United States, Florida
Mayo Clinic Recruiting
Jacksonville, Florida, United States, 32224
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
United States, Minnesota
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55902
United States, New York
Icahn School of Medicine at Mount Sinai Recruiting
New York, New York, United States, 10029
United States, North Carolina
Carolina BioOncology Institute Recruiting
Huntersville, North Carolina, United States, 28078
United States, Oklahoma
Stephenson Cancer Center, University of Oklahoma Health Sciences Center Recruiting
Oklahoma City, Oklahoma, United States, 73104
Sponsors and Collaborators
Atreca, Inc.
Layout table for investigator information
Study Director: Jonathan Benjamin, MD, PhD Atreca, Inc.
Layout table for additonal information
Responsible Party: Atreca, Inc. Identifier: NCT04244552    
Other Study ID Numbers: ATRC-101-A01
First Posted: January 28, 2020    Key Record Dates
Last Update Posted: February 1, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No